Table 3.
Treatment proffered to patients with pulmonary presentation of KD
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravenous antimicrobials | + | + | + | + | + | + | + | + | + | + | + |
| ICDT | + | + | − | + | − | − | − | + | + | − | − |
| Intrapleural Streptokinase | + | − | − | − | − | − | − | + | + | − | − |
| Surgical intervention | + VATS | − | − | − | − | − | − | − | + decortication | − | − |
| Aspirin | + | + | + | + | + | + | + | + | + | + | + |
| Day of administration of IVIG after symptom onset | 30 | 17 | 12 | 50 | 26 | 16 | 19 | 21 | 25 | 18 | 13 |
| Need for 2nd dose of IVIG | − | − | + | − | − | − | + | − | − | − | − |
ICDT, inter‐costal drainage tube; VATS, video‐assisted thoracoscopic surgery; IVIG, intravenous immunoglobulin.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.